ArticleMolecular oncology2013
SPARCL1 suppresses metastasis in prostate cancer.
Article in Molecular oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.BMC cancer · 2015Pooled it
- SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance.Cancer gene therapy · 2026Review
- The secreted protein SPARCL1 suppresses tumor progression in papillary thyroid carcinoma via SLC3A2-mediated ferroptosis.Endocrine-related cancer · 2026Article
- Article
- The oncogenic functions of SPARCL1 in bladder cancer.Journal of cellular and molecular medicine · 2024Article
- Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.Scientific reports · 2024Article
- SPARCL1 promotes chondrocytes extracellular matrix degradation and inflammation in osteoarthritis via TNF/NF-κB pathway.Journal of orthopaedic translation · 2024Article
- Article
- Experimental in vitro, ex vivo and in vivo models in prostate cancer research.Nature reviews. Urology · 2023Review
- CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- Article
- Menin Enhances Androgen Receptor-Independent Proliferation and Migration of Prostate Cancer Cells.Molecules and cells · 2022Article
- Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.Pathology oncology research : POR · 2022Article
- Role of germline variants in the metastasis of breast carcinomas.Oncotarget · 2022Article
- SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.BioMed research international · 2022Article
- Article
- DNA hypermethylation associated with upregulated gene expression in prostate cancer demonstrates the diversity of epigenetic regulation.BMC medical genomics · 2020Article
- SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.Experimental and therapeutic medicine · 2018Article
- Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.BMC gastroenterology · 2018Article
- Translational models of prostate cancer bone metastasis.Nature reviews. Urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeMetastasis, the main cause of death from cancer, remains poorly understood at the molecular level. EXPERIMENTAL
designBased on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo.
resultsSPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models.
conclusionsWe present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.